Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis B news

Show

From To
IDSA: Hep B Vaccine Benefit Persists in HIV Patients (CME/CE)

The effects of the hepatitis B vaccine appeared to last long-term in HIV-infected patients even if they have high CD4-positive cell counts, researchers said here.

Published
26 October 2011
From
MedPage Today HIV/AIDS
'PATH B', a comprehensive support program in Europe for patients with chronic hepatitis B launched

A pioneering educational resource, designed to improve the lives of people living with chronic hepatitis B, was launched today at an annual conference organised by Bristol-Myers Squibb in Hong Kong where 26 patient advocacy groups from 14 countries and regions gathered to discuss viral hepatitis.

Published
21 October 2011
From
Eurekalert Medicine & Health
Shark chemical 'a good antiviral'

A naturally occurring chemical in the dogfish shark could be a safe and potent weapon against human viruses, say scientists.

Published
20 September 2011
From
BBC Health
Third of the world infected with hepatitis: WHO

Around one third of the global population, or 2 billion people, have been infected with one of the viruses that causes the liver disease hepatitis, which kills about a million victims annually, the World Health Organization said on Tuesday.

Published
27 July 2011
From
Reuters
Hepatitis Scotland launched to tackle viral hepatitis

Hepatitis Scotland, a new voluntary organisation funded by the Scottish Government to help improve prevention, treatment and support for viral hepatitis is launched today.

Published
29 June 2011
From
Scottish Drugs Forum
HBV Genotype Predicts HBeAg Seroconversion on Tenofovir

Chronic hepatitis B patients with HBV genotype A and lower HBsAg levels at baseline were more likely to experience HBeAg seroconversion during treatment with tenofovir (Viread), researchers reported at EASL 2011.

Published
14 April 2011
From
HIVandhepatitis.com
Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B

Gilead's GS-9620, an experimental TLR7 agonist, stimulated interferon production and activated B-cells and T-cells in laboratory and human studies, and was active against hepatitis B and a related virus in monkeys and woodchucks, researchers reported at EASL.

Published
14 April 2011
From
HIVandhepatitis.com
Nanotechnology may lead to new treatment of liver cancer

Nanotechnology may open a new door on the treatment of liver cancer, according to a team of Penn State College of Medicine researchers. They used molecular-sized bubbles filled with chemotherapy drugs to prevent cell growth and initiate cell death in test tubes and mice.

Published
22 February 2011
From
Eurekalert Medicine & Health
Abbott receives FDA approval for first automated molecular test for assessing hepatitis B treatment

Abbott announced today it has received approval from the U.S. Food and Drug Administration (FDA) to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus (HBV) in a patient's blood.

Published
01 September 2010
From
Abbott
← Prev1...678910Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.